ArticleEpilepsia open2025
A cross-national cost-effectiveness analysis of brivaracetam focusing on psychiatric and behavioral adverse effects.
Yasushi Maruyama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it